

MEDICAL ONCOLOGY
PAPER-IITime: 3 hours
Max. Marks:100

MED.ONCO./J/20/17/II

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Define various phases of chronic myeloid leukemia. 3+4+3
b) Selection of first line TKI.
c) When is it safe to stop treatment?
2. a) Classify plasma cell neoplasms. 2+4+4
b) Outline the diagnostic tests for myeloma.
c) Your approach to treatment of multiple myeloma, relapsed after an Autologous Stem Cell Transplantation.
3. a) Evaluation of a patient presenting with solitary pulmonary nodule. 3+3+4
b) Mention the Immunohistochemistry panel to establish tissue diagnosis.
c) Algorithm for treatment of this case.
4. a) Describe management of CIN V. 4+3+3
b) What are drugs with ultra-low risk emetogenesis?
c) Side effects of anti-emetic drugs.
5. a) Chemotherapy regimens in Ewing's sarcoma. 3+4+3
b) EURAMOS Trial in Osteosarcoma.
c) Histology directed therapies in soft tissue sarcoma.
6. a) Diagnostic workup of obstructive jaundice due to extrinsic compression of distal biliary tract. 3+4+3
b) Algorithm for treatment of cancer of the head of pancreas.
c) Management of pain in a case of carcinoma of pancreas.
7. a) Pathophysiology of hormone resistance in prostate cancer. 3+4+3
b) Algorithm for management of castration resistant prostate cancer.
c) Gynecomastia in a patient of prostate cancer.
8. a) Tumour Lysis Syndrome. (TLS). 2+4+4
b) Risk stratification of TLS.
c) Prevention and management of TLS.

P.T.O

MEDICAL ONCOLOGY
PAPER-II

9. a) Molecular Classification of Triple Negative Breast Cancer (TNBC). 3+4+3
b) Treatment of TNBC.
c) Counselling a patient of TNBC.
10. a) Hyperviscosity syndromes. 3+4+3
b) Extravasation of various chemotherapeutic agents and their management.
c) Testicular cancer survivorship.

www.FirstRanker.com